Gritstone bio Inc. (GRTS)
| Bid | n/a |
| Market Cap | 3.8M |
| Revenue (ttm) | 1.7M |
| Net Income (ttm) | -133.03M |
| EPS (ttm) | -1.09 |
| PE Ratio (ttm) | -0.029541284403669724 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | n/a |
| Volume | 55,246,959 |
| Avg. Volume (20D) | 17,011,671 |
| Open | 0.04 |
| Previous Close | 0.05 |
| Day's Range | 0.03 - 0.04 |
| 52-Week Range | 0.03 - 3.17 |
| Beta | 0.50 |
About GRTS
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-she...
Analyst Forecast
According to 4 analyst ratings, the average rating for GRTS stock is "Hold." The 12-month stock price forecast is $0.75, which is an increase of 2229.19% from the latest price.
Stock Forecasts
6 months ago · businesswire.com
Gritstone bio Takes Action to Preserve Value and Strengthen Capital StructureEMERYVILLE, Calif.--(BUSINESS WIRE)--Gritstone bio, Inc. (Nasdaq: GRTS) (“Gritstone” or the “Company”), a clinical-stage biotechnology company working to develop the world's most potent vaccines, toda...
